Eli Lilly spotlights early oncology in first pipeline review since R&D shift
Two weeks into the Josh Bilenker era at Eli Lilly, the legacy pharma was excited to spotlight three early-stage “priority” oncology programs as they issued their 2020 guidance. They also reiterated their investment in Alzheimer’s development, including their drug for the newly reinvigorated amyloid hypothesis.
The new guidance offers a hint as to what the hundreds-strong oncology group at Lilly will look like now that the Loxo C-suite has taken the reigns, and how the new executives will approach R&D. It also points to the unrelenting grip Alzheimer’s, both its debilitating impact on millions and its once-in-a-lifetime market potential, has had on the minds of Big Pharma despite years of trial failure.
“We’ve gots some important bets on A-beta that are going to play out in the near-term,” CSO Dan Skovronsky told investors. “We think this is an important test of the amyloid hypothesis.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
